IGF1 and metabolic syndrome: Researchers have been referring to this hypothesis and adding layers, suggesting potential pathophysiological mechanisms that could also be altering the IGF peripheral system in SZ patients, such as cortisol, insulin-glucose metabolic dysregulations, dyslipidemia, inflammation, and cognitive alterations (Figure 3C).